Diabetes is a complex disease characterized by a combination of different and little understood, causes. The current classification system for the disease characterizes diabetes into three broad types: type 1 diabetes, type 2 diabetes, and gestational diabetes, but these three categories do not adequately reflect its sheer heterogeneity. This has severe negative implications for the planning of treatment regimens and identifying which patients are at risk of developing complications or comorbidities. Building on previous research which identified five novel diabetes subgroups in Scandinavian diabetes patient cohorts, this study sought to comprehensively characterize differences in inflammation biomarkers between these subgroups using Olink’s inflammation biomarker panel.
Dr. Andrzej Krolewski (Find his profile here), the head of the Genetics and Epidemiology section of the Harvard Medical School, has been working on the genetics of type 1 and type 2 diabetes. For the last 30 years, he has been actively investigating diabetic kidney disease in patient cohorts from the Joslin diabetes center, where he is also a researcher.